Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
150 hedge funds and large institutions have $2.38B invested in Intercept Pharmaceuticals, Inc. in 2017 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 51 increasing their positions, 55 reducing their positions, and 26 closing their positions.
31% more call options, than puts
Call options by funds: $105M | Put options by funds: $80.2M
5% more capital invested
Capital invested by funds: $2.26B → $2.38B (+$121M)
7% less repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 55
8% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 26
6% less funds holding
Funds holding: 159 → 150 (-9)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$124M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$71.1M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$44.7M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$9.92M |
| 5 |
Goldman Sachs
New York
|
+$9.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$18.4M |
| 2 |
HCM
Highfields Capital Management
Boston,
Massachusetts
|
-$11.7M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$10.6M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$10.6M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$10.4M |
ICPT Hedge Fund Activity: Q1 2017 in Review
150 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q1 2017, worth a combined $2.38B — up 5.3% from $2.26B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of ICPT and 24 opened new positions — a net loss of 2 holders — while 55 trimmed existing stakes and 51 added.
The largest buyer was BlackRock, adding an estimated $124M. The largest seller was Capital World Investors, cutting an estimated $18.4M.
- 150 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q1 2017, down from 159 in Q4 2016.
- Funds reported $2.38B of Intercept Pharmaceuticals, Inc. stock for Q1 2017, up 5.3% quarter-over-quarter.
- 24 funds opened new Intercept Pharmaceuticals, Inc. positions in Q1 2017 and 26 closed out, a net change of -2 holders.
- The largest Intercept Pharmaceuticals, Inc. buyer in Q1 2017 was BlackRock, an estimated $124M added.
- The largest Intercept Pharmaceuticals, Inc. seller in Q1 2017 was Capital World Investors, an estimated $18.4M sold.
Based on aggregated 13F filings for Q1 2017.